An Extended Access Program (EAP) for Perampanel

Inclusion criteria:

1. Participants who have completed their participation in Study E2007-G000-332, StudyE2007-G000-311, E2007-G000-238, E2007-G000-338, or who are being rolled over fromEAP E2007-G000-401 and, who in the opinion of the treating physician, continue todemonstrate a positive benefit-to-risk ratio from treatment with perampanel.

2. Participants who provide informed consent where applicable per local requirements.

3. Female participants of childbearing potential must agree for the duration of theprogram and for a period of at least 1 month following last dose of perampanel to beabstinent or to commit to the consistent and correct use of a medically acceptablemethod of birth control (example, a double-barrier method [condom plus spermicide,condom plus diaphragm with spermicide]).

Exclusion criteria:

1. Participants who reside in countries where the appropriate formulation of perampanelis commercially available.

2. Female participants who are nursing, pregnant, or planning to become pregnant.